Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996487 · ClinicalTrials.gov registry record · Phase 4
Screening to Prophylax Against Clostridium Difficile Infection -
A Phase 4 study, sponsored by Corewell Health East.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,294
- Enrollment target
NCT02996487 is a Phase 4 study that has completed, run by Corewell Health East. The registered enrollment target is 1,294 participants.
The verdict
NCT02996487, a Phase 4 study, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,294 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.
Interventions
- OTHER Placebo
- DRUG Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,294 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996487
The ClinicalTrials.gov registry entry for NCT02996487 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02996487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02996487 about?
NCT02996487 is a clinical study titled "Screening to Prophylax Against Clostridium Difficile Infection -". The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.
What is the current status of trial NCT02996487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,294 participants. The study started on 2016-12-19. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT02996487?
The interventions under investigation include: Placebo (OTHER), Vancomycin (DRUG).
Who is sponsoring clinical trial NCT02996487?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.